针对肝脏肿瘤治疗的DNA 适配体(aptamer)靶向分子设计开题报告
2020-04-22 19:13:46
1. 研究目的与意义(文献综述)
1、研究意义:肝脏恶性肿瘤由于其高死亡率已严重威胁人类的健康和生命。
提高恶性肿瘤诊断的准确率对于增加患者的生存率具有非常重要的意义。
肿瘤源于基因的突变。
2. 研究的基本内容与方案
基本内容:1、了解dna aptamer的环状结构,以及设计原理。
2、掌握dna适配体环状结构上的脱氧核苷酸组成对环的大小的影响。
3、获取有效适配体的简历序列,并分析核酸适配体的二级结构与结合能力间的关系。
3. 研究计划与安排
第一步:完成肝脏肿瘤靶点的确定及适配体生物学结构的认识。
预计4至6周完成。
第二步:设计这对特定靶蛋白的dna适配体的设计。
4. 参考文献(12篇以上)
参考文献:[1]Ellington AD,Szostak JW. In vitro selection of RNA molecules that bind specific ligands[J]. Nature,1990,346: 818.[2]Tuerk C,Gold L.Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase[J].Science,1990,249: 505.[3]Lee YJ,Lee SW. Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein[J].Biochem Bioph Res Co,2012,417: 521[4]方念.核酸适配子的定义及其肝细胞肿瘤诊断价值的初步研究[D]. 南昌: 南昌大学,2008.[5]Savory N,Abe K,Sode K,et al. Selection of DNA aptamer against specifiantigen using a genetic algorithm and application to sensing BiosensorsBioelectronics,2010,26: 1386.[6]Chen ZG,Lei YL,Chen X,et al.An aptamer based resonance light scatteringassay of prostate specific antigen[J].Biosensors and Bioelectronics,2012,36( 1) : 35.[7]Cheng JJ,Teply BA,Sherifi I,et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery[J].Biomaterials,2007,28: 869.[8]Min K,Jo H,Song K,et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA( ) and PSMA( -) prostate cancers[J].Biomaterials,2011,32: 2124.[9]Tan L,Neoh KG,Kang ET,et al. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells[J]. Macromol Biosci,2011,11: 1331.[10]Yu CC,Hu Y,Duan GH,et al. Novel aptamer-nanoparticle bio-conjugatesenhances delivery of anticancer drug to MUC1-Positive cancer cells in vitro[J]. PLoS ONE,2011,6( 9) : e24077.[11]Li.JJ,Xu M,Huang HP,et al.Aptamer-quantum dots conjugatebasedultrasensitive competitive electrochemical cytosensor for the detection of tumor cell Talanta,2011,85: 2113.[12]Hicke BJ,Marion C,Chang YF,et al. Tenascin-C aptamers are generated using tumor cells and purified protein[J]. J Biol Chem,2001,276( 52) : 48644.[13]刘喆.杨先达.新型HER2适配体的筛选和鉴定.中国医学科学院.第32卷.第6期.2012.[14]Daniels DA,Chen H,Hicke BJ,et al. A tenascin-C aptamer iden-tified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment[J]. National Acad Sciences,2003,100( 26) : 15416.[15]Chen XC,Deng YL,Lin Y,et al.Quantum dot-label aptamernanoprobesspecifically targeting glioma cells[J].Nanotechnolo-gy,2008,19( 23) :235105. 1.[16]Wang LF,Liu BR,Yin HT,et al. Selection of DNA aptamer that specific binding human carcinoembryonic antigen in vitro[J].